BBNX Earnings Date: Feb 16, 2027 (Estimated) — Beta Bionics, Inc.
NASDAQ · Healthcare · Medical - Equipment & Services
Updated
When is BBNX's next earnings date?
Beta Bionics, Inc. (BBNX) is expected to report Q4 2026 earnings on Tuesday, February 16, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.47 on revenue of $32.6M.
How did BBNX do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Beta Bionics, Inc. posted EPS of -$0.52 versus the -$0.52 estimate, a beat of 0.6%. Revenue was $35.5M against a $34.7M estimate. The stock's 1-day post-earnings move was -16.5%.
How much does BBNX stock move after earnings?
BBNX beat EPS estimates in 5 of its last 7 reported quarters. Over the last 7 reports the stock moved an average of 9.1% (up or down) in the day after earnings.
About Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
🤖 AI Earnings Analysis
Beta Bionics’ diabetes-device business posted a modest revenue beat at $36M, up from $27M year over year, but the reported growth rate is distorted by a low base. Loss widened to $0.52 per share from $0.33; despite beating estimates by $0.01, persistent heavy losses and securities litigation make results concerning.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | -0.52 | -0.52 | +0.64% | $35.5M | ✅ Beat | -16.55% | — | — |
| 2026-07-29 | Q2 2026 | -0.56 | -0.53 | +5.36% | $32.0M | ✅ Beat | -5.93% | -8.31% | +28.81% |
| 2026-04-21 | Q1 2026 | -0.48 | -0.49 | -2.08% | $27.6M | ❌ Miss | -0.57% | -17.85% | -17.60% |
| 2026-02-17 | Q4 2025 | -0.39 | -0.30 | +23.08% | $32.1M | ✅ Beat | -2.58% | -4.15% | -23.91% |
| 2025-10-28 | Q3 2025 | -0.43 | -0.33 | +23.26% | $27.3M | ✅ Beat | +10.34% | +14.54% | +27.10% |
| 2025-07-29 | Q2 2025 | -0.48 | -0.39 | +18.75% | $23.2M | ✅ Beat | +14.32% | +7.84% | +29.40% |
| 2025-03-25 | Q4 2024 | -0.42 | -2.72 | -547.62% | $20.4M | ❌ Miss | -13.60% | -26.15% | -27.33% |
Showing last 7 quarters.